Trevi Therapeutics (NASDAQ:TRVI) Stock Rating Lowered by Wall Street Zen

Key Points

• Wall Street Zen downgraded Trevi Therapeutics from hold to sell, even though the broader analyst community remains more upbeat with a consensus Buy rating and a $22.90 average price target.
• The stock has mixed analyst coverage: several firms, including D. Boral Capital, Oppenheimer, Morgan Stanley, and HC Wainwright, recently reiterated bullish ratings and price targets ranging from $19 to $21.
• Trevi recently reported a Q1 loss of $0.09 per share, missing estimates, but analysts are raising forward EPS expectations, suggesting improving sentiment based more on future prospects than on the latest quarter.

Trevi Therapeutics (NASDAQ:TRVI - Get Free Report) was downgraded by analysts at Wall Street Zen from a "hold" rating to a "sell" rating in a research note issued to investors on Saturday.

A number of other analysts have also commented on TRVI. Weiss Ratings reissued a "sell (d-)" rating on shares of Trevi Therapeutics in a report on Monday, April 20th. D. Boral Capital reissued a "buy" rating and set a $19.00 price objective on shares of Trevi Therapeutics in a report on Friday, April 17th. Oppenheimer reissued an "outperform" rating on shares of Trevi Therapeutics in a report on Monday, March 9th. Morgan Stanley restated an "overweight" rating and issued a $20.00 target price on shares of Trevi Therapeutics in a research note on Wednesday. Finally, HC Wainwright restated a "buy" rating and issued a $21.00 target price on shares of Trevi Therapeutics in a research note on Wednesday. Two analysts have rated the stock with a Strong Buy rating, nine have assigned a Buy rating and one has given a Sell rating to the stock. According to MarketBeat.com, the stock has an average rating of "Buy" and a consensus price target of $22.90.

Trevi Therapeutics Stock Performance

Shares of TRVI opened at $14.50 on Friday. The stock has a 50 day moving average price of $12.69 and a two-hundred day moving average price of $11.95. The firm has a market capitalization of $2.06 billion, a P/E ratio of -45.31 and a beta of 1.07. Trevi Therapeutics has a 52 week low of $5.38 and a 52 week high of $16.12.

Trevi Therapeutics (NASDAQ:TRVI - Get Free Report) last issued its quarterly earnings data on Tuesday, May 5th. The company reported ($0.09) EPS for the quarter, missing analysts' consensus estimates of ($0.07) by ($0.02). On average, equities analysts forecast that Trevi Therapeutics will post -0.44 earnings per share for the current year.

Hedge Funds Weigh In On Trevi Therapeutics

Several institutional investors have recently bought and sold shares of the company. AlphaCentric Advisors LLC lifted its stake in Trevi Therapeutics by 5.7% in the first quarter. AlphaCentric Advisors LLC now owns 23,970 shares of the company's stock valued at $286,000 after purchasing an additional 1,303 shares during the last quarter. KBC Group NV purchased a new stake in shares of Trevi Therapeutics during the first quarter worth $29,000. Fifth Third Bancorp purchased a new stake in shares of Trevi Therapeutics during the first quarter worth $1,531,000. Candriam S.C.A. purchased a new stake in shares of Trevi Therapeutics during the first quarter worth $9,229,000. Finally, Hsbc Holdings PLC purchased a new stake in shares of Trevi Therapeutics during the first quarter worth $205,000. Hedge funds and other institutional investors own 95.76% of the company's stock.

Trevi Therapeutics News Roundup

Here are the key news stories impacting Trevi Therapeutics this week:

• Positive Sentiment: HC Wainwright lifted near-term EPS estimates for Q2 2026 to ($0.11) from ($0.12), suggesting modestly better expected profitability. Trevi Therapeutics Q1 2026 Earnings Call Transcript
• Positive Sentiment: The firm also increased its Q3 2026 EPS estimate to ($0.14) from ($0.17), Q4 2026 to ($0.15) from ($0.17), and FY2026 to ($0.47) from ($0.54).
• Positive Sentiment: HC Wainwright kept a bullish long-term view, raising its FY2027 estimate to ($0.57) from ($0.63) and FY2028 to ($0.63) from ($0.66), while maintaining the same $21 price target.
• Neutral Sentiment: The analyst trimmed its FY2029 estimate to $0.70 from $0.79 in one report, but the overall tone remained constructive.
• Neutral Sentiment: Trevi recently reported a Q1 loss of ($0.09) per share, slightly wider than expectations, so the stock’s move appears driven more by improved forward estimates and analyst confidence than by the latest earnings print.

Trevi Therapeutics Company Profile

Trevi Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on the development of novel non-opioid therapies for the management of chronic and acute pain. The company leverages proprietary drug delivery platforms and targeted molecular approaches to address high unmet needs in cancer-related pain, chemotherapy-induced neuropathy and other severe pain conditions.

Its lead product candidate is a proprietary formulation of tetrodotoxin (TTX), a sodium-channel blocking agent being evaluated in early-stage clinical trials for moderate-to-severe pain associated with advanced cancer and peripheral neuropathy.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.